North America remains the largest market for Sodium Iodide (131I) Diagnostic Capsules, accounting for roughly 35% of global sales. The region’s advantage stems from mature nuclear medicine infrastructure, robust reimbursement frameworks, and ongoing FDA‑endorsed clinical trials that sustain Sodium Iodide (131I) Diagnostic Capsules market growth. Europe follows with a 25% share, driven by harmonized EU radiopharmacy guidelines, strong public‑hospital networks, and substantial government investment in cancer screening programs. Asia Pacific, representing 30% of the market and identified as the fastest‑growing region, benefits from rapid hospital expansion, rising thyroid‑cancer incidence in China and India, and supportive regulatory pathways that accelerate product approvals. Latin America contributes about 5%, with Brazil and Mexico leading adoption due to expanding private‑clinic networks and increasing awareness of nuclear diagnostic procedures. The Middle East & Africa also hold roughly 5%, where emerging healthcare hubs in the Gulf, coupled with government‑backed oncology initiatives and improving logistics for radioactive material, are laying the groundwork for future demand. Across all territories, the regional forecast points to continued diversification of supply chains and heightened collaboration between manufacturers and diagnostic centers, reinforcing the market’s resilience and long‑term growth trajectory.
